Lawrence Otto Klein

Lawrence Otto Klein is a declared insider at 4 companies (senior executive); the most frequent names are CRISPR Therapeutics AG, Oruka Therapeutics, Inc. and Dyne Therapeutics, Inc. We count 35 filings; the first trade dates from 2 January 2019 and the latest from 1 October 2026.

Every open-market trade on record is a sale: 20 sales worth €15.0M. Other entries cover 3 share grants and 11 option exercises. Since January 2026: no purchases and 8 sales on the market.

Most recently, on 2 October 2026, the filings show an open-market sale worth €15k in Oruka Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.